{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'A pregnancy test will be performed on each premenopausal female patient of childbearing', 'potential prior to the first dose of study drug, on Day 1 of Cycles >2 while on treatment, and', 'again at treatment discontinuation during the End-of-Treatment visit. A negative pregnancy test', 'must be documented prior to administration of study drug.', 'If a patient is confirmed pregnant during the study, study drug administration must be', \"discontinued immediately. The Investigator must immediately notify the Sponsor's Medical\", 'Monitor of the event and record the pregnancy on the Pregnancy Form (provided by', \"Karyopharm). The initial information regarding a pregnancy must be forwarded to Karyopharm's\", 'Pharmacovigilance by email or fax within 24 hours of first knowledge of its occurrence.', 'The pregnancy should be followed up to determine the outcome, including spontaneous or', 'voluntary termination, details of the birth, and any birth defects, congenital abnormalities, or', 'maternal and/or newborn complications.', \"All pregnancies occurring within 3 months after the patient's last dose of study drug must be\", 'reported to Karyopharm, regardless of whether the patient received selinexor or other study', 'drugs, withdraws from the study, or the study is completed. Patients should be instructed to', 'inform the Investigator regarding any pregnancies.', 'Any SAE that occurs during pregnancy must be recorded on the SAE report form (eg, maternal', 'serious complications, therapeutic abortion, ectopic pregnancy, stillbirth, neonatal death,', 'congenital anomaly, or birth defect) and reported within 24 hours in accordance with the', 'procedure for reporting SAEs (described in Section 12.2.3).', 'A pregnancy in a female partner of a male patient must be reported to Karyopharm within', '24 hours of learning of its occurrence. Pregnancies in female partners should only be followed if', 'the male patient is being treated with a selinexor-containing regimen. Consent to report', 'information regarding these pregnancy outcomes should be obtained from the female partner.', 'It is not known whether selinexor passes into the breast milk. Mothers should not breastfeed', 'while being treated with selinexor-containing regimen.', '12.3.2.', 'Overdose, Abuse, Misuse, Medication Errors, and Occupational Exposure', 'All incidences of overdose, abuse, misuse, medication errors, and occupational exposure are', 'required to be reported to Karyopharm Pharmacovigilance on an SAE report form and emailed to', 'pharmacovigilance@karyopharm.com, regardless of whether or not there is an associated AE or', 'SAE.', '12.3.2.1. Overdose', 'An overdose is a deliberate or accidental administration of any study treatment to a study patient,', 'at a dose greater than that which was assigned to that patient per the study protocol. If an', 'overdose occurs, the Investigator and Karyopharm should be notified immediately, and the', 'patient should be observed closely for AEs. Resulting symptoms should be treated, as', 'appropriate, and the incident of overdose and related AEs and/or treatment should be', \"documented in the patient's medical record and in the eCRF. Information regarding the overdose\", 'is to be recorded on an SAE report form and sent to Karyopharm Pharmacovigilance regardless', 'of whether or not an AE or SAE has occurred due to the overdose. If the overdose is associated', 'with an SAE, the SAE report form must be submitted to Karyopharm Pharmacovigilance within', 'Confidential', 'Page 91', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '24 hours of awareness. If there is no AE or SAE, the report must be submitted within 24 hours of', 'awareness.', 'As selinexor is metabolized by GSH conjugation, it is possible, but not demonstrated, that', 'hepatic GSH depletion might occur in case of extreme overdose. Therefore, in overdose cases, if', 'patients develop liver function test abnormalities, supportive measures such as SAM or other', 'drugs that can replace GSH might be considered as part of the overall management plan.', '12.3.2.2. Abuse, Misuse, or Medication Error', 'Abuse is the persistent or sporadic, intentional excessive use of the study treatment which is', 'accompanied by harmful physical or psychological effects.', 'A medication error is any preventable incident that may cause or lead to inappropriate study', 'treatment use or patient harm while the study treatment is in the control of the health care', 'professionals or patients. Such incident may be due to health care professional practice, product', 'labeling, packaging and preparation, procedures for administration, and systems, including the', 'following: prescribing, order communication, nomenclature, compounding, dispensing,', 'distribution, administration, education, monitoring, and use.', 'All occurrences of abuse, misuse, or medication error with any study treatment are to be', 'recorded on an SAE report form and sent to Karyopharm Pharmacovigilance, regardless of', 'whether or not an AE or SAE has occurred due to the abuse, misuse, or medication error. If the', 'abuse, misuse, or medication error is associated with an SAE, the SAE report form must be', 'submitted to Karyopharm Pharmacovigilance within 24 hours of awareness. If there is no AE or', 'SAE, the report must be submitted within 24 hours of awareness.', '12.3.2.3. Occupational Exposure', \"Occupational exposure is the exposure to a study treatment as a result of one's professional or\", 'non-professional occupation. For this protocol, please follow the instructions for preparation and', 'administration of selinexor, bortezomib, and dexamethasone.', 'All occurrences of occupational exposure with any study treatment are to be recorded on an SAE', 'report form and sent to Karyopharm Pharmacovigilance, regardless of whether or not an AE or', 'SAE has occurred due to the occupational exposure. If the occupational exposure is associated', 'with an SAE, the SAE report form must be submitted to Karyopharm Pharmacovigilance within', '24 hours of awareness. If there is no AE or SAE, the report must be submitted within 24 hours of', 'awareness.', 'Confidential', 'Page 92', 'Version 4.0']\n\n###\n\n", "completion": "END"}